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ABSTRACT Health care-associated methicillin-resistant Staphylococcus aureus (MRSA)
infections are a burden on the health care system. Clinical laboratories play a key
role in reducing this burden, as the timely identiﬁcation of MRSA colonization or in-
fection facilitates infection control practices that are effective at limiting invasive
MRSA infections. The Xpert MRSA NxG assay recently received FDA clearance for the
direct detection of MRSA from nasal swabs. This multicenter study evaluated the
clinical performance characteristics of the Xpert MRSA NxG assay with prospectively
collected rayon nasal swabs (n  1,103) and ﬂocked swab (ESwab) nasal specimens
(n  846). Culture-based identiﬁcation methods and antimicrobial susceptibility test-
ing were used as the reference standards for comparison. According to the refer-
ence method, the positivity rates for MRSA in the population evaluated were 11.1%
(122/1,103) for rayon swabs and 11.6% (98/846) for ﬂocked swabs. The overall sensi-
tivity and speciﬁcity of the rayon swabs were 91.0% (95% conﬁdence interval [CI],
84.6 to 94.9%) and 96.9% (95% CI, 95.7 to 97.8%), respectively, across eight testing
sites. The ﬂocked swab specimens were 92.9% sensitive (95% CI, 86.0 to 96.5%) and
97.6% speciﬁc (95% CI, 96.2 to 98.5%) for MRSA detection across six testing sites.
The sensitivity and speciﬁcity of the combined ﬂocked and rayon swab data were
91.8% (95% CI, 87.4 to 94.8%) and 97.2% (95% CI, 96.3 to 97.9%), respectively. The
positive predictive value (PPV) for rayon swabs was 78.7%, versus 83.5% for ESwabs.
The negative predictive values (NPVs) for rayon swabs and ESwab specimens were
98.9% and 99.1%, respectively. In conclusion, the Xpert MRSA NxG assay is a sensi-
tive and speciﬁc assay for the direct detection of MRSA from nasal swab specimens.
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Hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) infections are amajor cause of morbidity and mortality worldwide (1–3). Recent data from the
Centers for Disease Control and Prevention (CDC) estimated that the annual incidence
of invasive hospital-acquired MRSA infections was over 55,000, resulting in over 7,700
deaths (4). The identiﬁcation of carriers and those with active MRSA disease has the
potential to reduce infections through infection control practices such as targeted
decolonization protocols and patient isolation (5). Therefore, active surveillance of
inpatients for MRSA is a strategy for preventing health care-acquired infections (HAIs)
by MRSA.
Traditional methods for MRSA surveillance routinely consisted of culture-based
screening programs in which nasal swabs were inoculated into medium that is selective
and differential for S. aureus (6), with methicillin resistance being conﬁrmed by using
phenotypic methods. However, this process is burdensome and may take up to 3 days
to produce results (7, 8). Chromogenic medium that is speciﬁc for MRSA may shorten
the process by eliminating the need for susceptibility testing, but the requirement for
overnight incubation and the relative lack of sensitivity are limiting compared to many
molecular methods (9–13).
There are several FDA-cleared commercial assays available for the molecular detec-
tion of MRSA in nasal swabs (14); the Xpert MRSA NxG assay is a new FDA-cleared
nucleic acid ampliﬁcation test for the detection of MRSA from both rayon nasal swabs
and ESwab specimens (15). Compared to the previous Xpert MRSA assay, the next-
generation assay includes additional proprietary primers and probes that are inclusive
of more staphylococcal cassette chromosome mec (SCCmec) types as well as both
the mecA and mecC genes, which encode methicillin-oxacillin resistance. The sample-
to-answer assay requires only a few minutes of hands-on time and takes about 1 h to
produce results on a random-access platform. The objective of this study was to
evaluate the clinical performance characteristics of the Xpert MRSA NxG assay for the
detection of MRSA colonization.
MATERIALS AND METHODS
Specimens. Following institutional review board (IRB) approval at each site, anterior naris specimens
were collected from individuals at risk for nasal colonization by MRSA during two separate prospective,
multisite investigational studies. The study population consisted of subjects at risk for MRSA nasal
colonization, such as patients who were previously isolated due to MRSA nasal colonization, patients with
an extended stay in an acute-care or extended-stay facility, or an outpatient clinic population. For the ﬁrst
study, specimens were collected by using paired sterile rayon swabs (Cepheid, Sunnyvale, CA). One swab
was used for the Xpert MRSA NxG assay, and the other was used for reference culture. Prior to testing,
the swabs were gently brushed together with a twirling motion to ensure an equal distribution of the
specimen on the swabs. Rayon swab specimens were collected and tested at 8 clinical trial sites
representing different geographic locations both within and outside the United States. In the second
study, nasal specimens were collected by using a Copan liquid Amies elution swab (ESwab; Copan
Diagnostics, Murietta, CA). ESwab specimens were collected and tested at 6 clinical trial sites within the
United States. One site participated in the collection of both rayon swab and ESwab specimens. At this
site, either a rayon swab or an ESwab, but not both, was collected from each study participant.
Study sites. For the rayon swab study, specimens were tested at the Washington University School
of Medicine (St. Louis, MO), The George Washington University Medical Center (Washington, DC), the
Louis Stokes Cleveland DVA Medical Center (Cleveland, OH), the University of California—Davis (Sacra-
mento, CA), TheraFirst (Fort Lauderdale, FL), and Geisinger Health (Danville, PA). Non-U.S. study sites
included Changi General Hospital (Singapore) and the Institut für Medizinische Mikrobiologie, Univer-
sitätsklinikum Münster (Münster, Germany). ESwab specimens were tested in the United States at
ProMedica Laboratories (Toledo, OH), Tampa General Hospital (Tampa, FL), TheraFirst (Fort Lauderdale,
FL), the University of Chicago (Chicago, IL), the Harbor-UCLA Medical Center (Torrance, CA), and the
University of Oklahoma Health Sciences Center (Oklahoma City, OK).
Xpert MRSA NxG assay. The Xpert MRSA NxG assay (Cepheid, Sunnyvale, CA) was performed
according to the manufacturer’s instructions (15). Brieﬂy, one swab from the set of rayon swabs was
inserted into the elution reagent vial and broken off at the score mark on the swab shaft. For the ESwab
device, the specimen was vortexed for 5 s, and 300 l of the specimen was added to the elution reagent
vial. The vial was subjected to vortex mixing for 10 s, and the entire contents were transferred to the
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sample chamber of an Xpert MRSA NxG assay cartridge by using the provided transfer pipette. The
cartridge was loaded into a GeneXpert instrument for testing. If the initial Xpert MRSA NxG assay result
was indeterminate, the specimen was retested one additional time. On each day of testing, acceptable
results from one positive control and one negative control were required prior to the testing of
experimental specimens. Each Xpert MRSA NxG cartridge includes a sample processing control (SPC) and
a probe check control (PCC). The SPC ensures adequate processing of the sample and monitors for the
presence of inhibitors in the PCR mixture. The PCC veriﬁes reagent rehydration, PCR tube ﬁlling in the
cartridge, probe integrity, and dye stability. Results of testing were considered invalid if either the SPC
or PCC failed. All specimens were tested by using the Xpert MRSA NxG assay within 24 h of collection.
Remnant ESwabs and the second rayon swab were shipped on wet ice to a reference laboratory
(NorthShore University HealthSystem) for reference method testing.
Comparative reference method. The gold-standard method used for comparison consisted of
inoculation into the FDA-cleared MRSA-selective chromogenic agar BBL CHROMagar MRSA II (Becton
Dickinson, Franklin Lakes, NJ), incubation according to the manufacturer’s instructions, and inoculation
into Trypticase soy broth (TSB) containing 6.5% NaCl. After 18 to 24 h of incubation at 35°C, TSB was
subcultured on a blood agar plate (BAP) containing 5% sheep’s blood and BBL CHROMagar MRSA II
selective agar. Isolates grown on selective agar were subcultured to a BAP for subsequent identiﬁcation.
Presumptive S. aureus colonies were conﬁrmed by Gram staining and positive catalase and positive tube
coagulase testing according to standard procedures. Susceptibility testing was performed on all con-
ﬁrmed S. aureus isolates by using cefoxitin (30 g) disk diffusion as a surrogate for methicillin resistance.
Susceptibility testing was performed and results were interpreted by using criteria reported in CLSI
document M100-S24 (35). All specimens were tested by the reference method within 48 h of collection.
The reference method result was considered positive for MRSA if the presence of MRSA was conﬁrmed
by either direct culture or enrichment culture.
Statistical analysis. For assessment of agreement with the reference method (culture and suscep-
tibility), the sensitivity, speciﬁcity, PPV, and NPV were calculated by using standard methods. The 95%
conﬁdence intervals were calculated by using the Wilson score method. The poolabilities of results
among different sites for the rayon swab and ESwab specimens were compared by using Fisher’s exact
test.
RESULTS
Study population. A total of 1,103 evaluable rayon swab specimens were tested by
the Xpert MRSA NxG assay at 8 clinical sites. More than two-thirds of the subjects were
male (n  772; 70.0%), and the majority of the subjects were between 22 and 65 years
of age (n  735; 66.6%), with subjects 65 years of age (n  330; 29.9%) representing
the next most common population (Table 1). The overall positivity rate for MRSA based
on the reference culture method was 11.1% (range, 0% to 43.3%). The majority of
specimens were collected in an inpatient setting (60.7%). A total of 846 ESwab
specimens were tested from 6 clinical sites. With ESwabs, the overall positivity rate for
MRSA using culture-conﬁrmed results was 11.6% (range, 0.0% to 31.0%). The gender
distribution for the ESwab specimens was approximately equal (males, n 422; 49.9%).
The majority of subjects tested were between the ages of 22 and 65 years (n  635;
75.1%), and 20.0% were 65 years of age (n  169) (Table 1). The distributions of
TABLE 1 Demographics of study subjects
Subject parameter
No. (%) of specimens
Rayon swabs ESwabs All
Males 772 (70.0) 422 (49.9) 1,194 (61.3)
Females 331 (30.0) 424 (50.1) 755 (38.7)
Age range (yr)
2–5 5 (0.5) 1 (0.1) 6 (0.3)
6–12 6 (0.5) 1 (0.1) 7 (0.4)
13–21 27 (2.4) 40 (4.7) 67 (3.4)
22–65 735 (66.6) 635 (75.1) 1,370 (70.3)
65 330 (29.9) 169 (20.0) 499 (25.6)
Patient location
Inpatient 669 (60.7) 302 (35.7) 971 (49.8)
Outpatient 309 (28.0) 272 (32.2) 581 (29.8)
Emergency department 125 (11.3) 272 (32.2) 397 (20.4)
Total 1,103 846 1,949
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ESwab specimens collected were nearly equivalent between inpatients (35.7%), outpa-
tients (32.2%), and patients at the emergency department (32.2%).
Xpert MRSA NxG assay performance with rayon swab specimens. The Xpert
MRSA NxG assay yielded 1,075 valid results in the initial round of testing of 1,106 rayon
swab specimens, with 15 instrument error ﬂags (1.4%), 9 invalid results (0.8%), and 7
specimens with no result (0.6%). Repeat testing of the 31 samples produced a valid
result for 28 of these specimens. Of the 1,103 specimens tested with valid results, 12.8%
(n  141) were positive for MRSA by the Xpert MRSA NxG assay.
Testing of rayon swabs with the Xpert MRSA NxG assay demonstrated a combined
sensitivity of 91.0%, with a range of 83.3% to 100%, across the 8 testing sites (Table 2).
Repeat subculture from enrichment broth for the 11 false-negative results with the
Xpert MRSA NxG assay conﬁrmed MRSA positivity with the reference method. The
overall speciﬁcity of the assay using rayon swabs was 96.9%, with a range of 90.2% to
100% (Table 2). After repeat subculture from enrichment broth, 30 of 30 rayon swab
specimens with false-positive results by the Xpert MRSA NxG assay remained culture
negative. For the population tested, the MRSA positive predictive value (PPV) was
78.7% (95% conﬁdence interval [CI], 71.3 to 84.7%), and the negative predictive value
(NPV) was 98.9% (95% CI, 98.0 to 99.4%) (Table 2).
Xpert MRSA NxG assay performance with ESwab specimens. The Xpert MRSA
NxG assay yielded 846 valid results in the initial round of testing of 862 ESwab
specimens, with 8 errors (0.9%) and 8 invalid results (0.9%). Repeat testing of ESwab
specimens was not possible due to an insufﬁcient volume remaining in the sample. Of
the 846 specimens tested, 12.9% (n  109) were positive for MRSA by the Xpert MRSA
NxG assay.
For nasal specimens collected with ESwabs, the Xpert MRSA NxG assay had an
overall sensitivity of 92.9%, with a sensitivity range of 75% to 100%, across the 6 testing
sites (Table 3). Upon repeat subculture from enrichment broth, 6 of 7 specimens with
false-negative results obtained by the Xpert MRSA NxG assay remained MRSA culture
positive. The overall speciﬁcity of the assay using ESwabs was 97.6%, with a range of
80% to 100% (Table 3). Of 18 specimens with false-positive Xpert MRSA NxG test results,
17 remained culture negative after repeat subculture from enrichment broth. For the
population tested, the MRSA PPV was 83.5%, and the NPV was 99.1% (Table 3).
Combined performance of the rayon and ESwab specimens. Analysis of the
results from the rayon swab and ESwab specimens demonstrated that the data were
poolable across collection devices (P  0.81 for sensitivity and P  0.46 for speciﬁcity).
There were a total of 1,949 specimens tested, with 202 having a true-positive result, 48
having a false-positive result, 1,681 having a true-negative result, and 18 having a
false-negative result. The sensitivity and speciﬁcity of the pooled data were 91.8% (95%
CI, 87.4 to 94.8%) and 97.2% (95% CI, 96.3 to 97.9%), respectively. The PPV and NPV for










(95% CI) PPV (%) (95% CI) NPV (%) (95% CI)TP FP TN FN
A 90 34 5 46 5 87.2 (73.3–94.4) 90.2 (79.0–95.7) 87.2 (73.3–94.4) 90.2 (79.0–95.7)
B 78 3 0 75 0 100 (43.9–100) 100 (95.1–100) 100 (43.9–100) 100 (95.1–100)
C 228 23 6 199 0 100 (85.6–100) 97.1 (93.8–98.7) 79.3 (61.6–90.2) 100 (98.1–100)
Da 172 11 4 157 0 100 (74.1–100) 97.5 (93.8–99.0) 73.3 (48.1–89.1) 100 (97.6–100)
E 125 7 3 115 0 100 (64.6–100) 97.5 (92.8–99.1) 70.0 (39.7–89.2) 100 (96.8–100)
Fa 5 0 0 5 0 NA 100 (56.7–100) NA 100 (56.7–100)
G 125 5 3 116 1 83.3 (43.7–96.7) 97.5 (92.9–99.1) 62.5 (30.6–86.3) 99.1 (95.3–99.8)
Hb 280 28 9 238 5 84.8 (69.1–93.4) 96.4 (93.2–98.1) 75.7 (59.9–86.6) 97.9 (95.3–99.1)
Total 1,103 111 30 951 11 91.0 (84.6–94.9) 96.9 (95.7–97.9) 78.7 (71.3–84.7) 98.9 (98.0–99.4)
aNon-U.S. site.
bAlso participated in the evaluation of ESwab specimens.
cTP, true positive; FP, false positive; TN, true negative; FN, false negative; NA, not applicable.
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the combined specimens were 80.8% (95% CI, 75.5 to 85.2%) and 98.9% (95% CI, 98.3
to 99.3%), respectively.
DISCUSSION
This is one of the ﬁrst studies to evaluate the performance of the Xpert MRSA NxG
assay, a rapid molecular test for the direct detection of MRSA from nasal swabs using
primers and probes for the SCCmec insertion site and for the mecA and mecC genes
(16). A recent review of the clinical performance of a previous generation of the Xpert
MRSA assay described sensitivities and speciﬁcities ranging from 63 to 99% and 96 to
100%, respectively (14). False-negative results were partly attributed to variant SCCmec
types that were not detected by the previous assay (17, 18).
The next-generation Xpert MRSA NxG assay has been updated to identify additional
SCCmec subtypes, in addition to the detection of mecC, a recently discovered methi-
cillin resistance determinant emerging in Europe (19). The lack of identiﬁcation of new
and emerging SCCmec variants has plagued other available molecular tests for the
detection of MRSA in nasal swabs. Previous evaluations of the clinical performance of
commercially available molecular tests for the detection of MRSA from nasal swabs
have observed a wide variability in sensitivities, ranging from as low as 63% to 90%
(14, 20, 21). One study that tested more than 25,000 specimens collected in a large
health system in the United States found that the LightCycler MRSA Advanced test and
a previous generation of the Xpert MRSA assay had sensitivities of 98.3% and 95.7%,
respectively (22). The overall sensitivity of the Xpert MRSA NxG assay evaluated in this
investigation was 91.8%. This sensitivity is higher than that determined in a recent
retrospective study that evaluated the performance of ESwabs on the Xpert MRSA NxG
assay for intensive care unit (ICU) and presurgical patients, which found that the assay
was 77.8% sensitive compared to culture-based methods (16). In our study, there were
11 (1%) false-negative results with the rayon swab specimens and 7 (0.8%) false-
negative results using ESwab specimens. All but one of these specimens was conﬁrmed
to be culture positive upon repeat testing, suggesting that MRSA was present but
below the limit of detection of the molecular assay. Another possible explanation is the
presence of yet another SCCmec subtype not targeted by the Xpert MRSA NxG assay.
This is supported by the fact that 10 of the 11 false-negative results using rayon swabs
occurred at just two testing sites, raising the possibility of a particular strain at these
sites that is not detected by the Xpert MRSA NxG assay.
The overall PPV and NPV predicted from the results of our study are 80.8% and
98.9%, respectively. A high NPV is advantageous for a number of reasons. With a
negative test result, a patient could be reliably removed from isolation precautions,
increasing patient satisfaction and decreasing health care costs. A recent study dem-
onstrated that rapid molecular MRSA screening resulted in a 44% reduction in the
number of patient isolation days (23). One study estimated that the cost of contact
precautions exceeds $100 per day (24). Thus, even one fewer day of patient isolation
can reduce hospital costs, although the economic value of active surveillance for MRSA









(95% CI) PPV (%) (95% CI) NPV (%) (95% CI)TP FP TN FN
Ha 231 19 8 203 1 95 (76.4–99.1) 96.2 (92.7–98.1) 70.4 (51.5–84.1) 99.5 (97.3–99.9)
I 139 6 1 132 0 100 (61.0–100) 99.2 (95.9–99.9) 85.7 (48.7–97.4) 100 (97.2–100)
J 136 3 0 132 1 75.0 (30.1–95.4) 100 (97.2–100) 100 (43.9–100) 99.2 (95.9–99.9)
K 15 0 3 12 0 NA 80 (54.8–93.0) NA 100 (75.8–100)
L 168 50 5 111 2 96.2 (87.0–98.9) 95.7 (90.3–98.1) 90.9 (80.4–96.1) 98.2 (93.8–99.5)
M 157 13 1 140 3 81.3 (57.0–93.4) 99.3 (96.1–99.9) 92.9 (68.5–98.7) 97.9 (94.0–99.3)
Total 846 91 18 730 7 92.9 (86.0–96.5) 97.6 (96.2–98.5) 83.5 (75.4–89.3) 99.1 (98.1–99.5)
aAlso participated in the evaluation of rayon specimens.
bTP, true positive; FP, false positive; TN, true negative; FN, false negative; NA, not applicable.
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in the hospital setting is an area of ongoing debate. Cost-beneﬁt analyses have
illustrated that MRSA screening is cost-effective in different settings with different
MRSA prevalence rates (25, 26). Conversely, other studies have not demonstrated this
cost beneﬁt and have even advocated for universal decolonization rather than screen-
ing (27). Any potential cost savings could help justify the increased costs of molecular
testing compared to those of culture, as the turnaround time (TAT) is greatly reduced
with the Xpert MRSA NxG assay, which is completed in about 1 h, compared to the
overnight incubation required for direct plating for agar-based culture systems or 48 h
or more for culture systems that require broth enrichment prior to plating onto solid
medium. In addition to its potential as a cost-effective measure for infection control
programs, molecular testing for MRSA colonization may also improve patient out-
comes, as was demonstrated by mathematical modeling that predicted that active
surveillance testing with rapid diagnostic testing for MRSA would decrease the prev-
alence of nosocomial MRSA faster than culture (28). Both the prompt isolation of
positive patients and decreased prevalences of MRSA-colonized patients are factors
that contribute to lower rates of hospital-acquired MRSA infections (29, 30). To this end,
the Xpert MRSA NxG assay can be performed on demand, with minimal setup time,
facilitating the early identiﬁcation of MRSA-positive patients to enable the rapid
implementation of infection control measures and patient bed management.
False-positive detection of MRSA can lead to unnecessary isolation and increased
costs. Previous evaluations of the speciﬁcity of commercial assays for the molecular
detection of MRSA in nasal swabs indicate that most assays exhibit a speciﬁcity of
95% (22, 31, 32). The MRSA NxG assay evaluated in this study showed similar
performance characteristics, with an overall speciﬁcity of 97.2%. Previous generations
of MRSA molecular assays were prone to false-positive results when tested on strains
containing an empty SCCmec cassette (i.e., mecA dropout strains), which are estimated
to occur in about 7% of methicillin-susceptible S. aureus (MSSA) isolates in the United
States (33). However, this problem was remedied in subsequent assays through the
inclusion of primers and probes targeting both the junction of the SCCmec cassette
with the orfx gene and the mecA gene. A few of the false-positive results generated in
this study could have occurred for specimens containing a mixture of a methicillin-
resistant coagulase-negative Staphylococcus strain and an empty-cassette-containing S.
aureus strain. Given the regions targeted by the primers and probes in the Xpert MRSA
NxG assay, this is theoretically possible but improbable. Another possibility is that the
false-positive results were the result of the detection of residual nucleic acid from
nonviable bacteria in patients who were recently treated with antimicrobial agents. In
our study, potential subjects were excluded if they had systemic or nasal antibiotic use
within the previous 7 days; however, antibiotic use prior to the previous 7 days was not
a criterion for exclusion.
The strengths of this study include the large number (n  1,949) of prospectively
collected samples from multiple centers that encompassed a wide geographical area
both within and outside the United States, which increased the likelihood that this
study captured a diverse collection of MRSA strain types. Another strength of this study
is the evaluation of multiple collection systems, including rayon swabs and ESwab
specimens. We found that the sensitivities and speciﬁcities were similar between the
two collection devices. This observation is supported by at least one study that found
comparable performances of the two collection systems for the detection of MRSA
using commercial molecular assays (34).
A potential limitation of this study is the fact that the ESwab specimens were
collected only from clinical centers within the United States. Thus, the performance of
the Xpert MRSA NxG assay with this collection device for MRSA strain variants that are
more common in Europe and worldwide may not have been captured with this study.
Additionally, only a minority of the rayon swab specimens were collected from females
(30%), and a paucity of specimens of either type were collected from patients aged 21
years or younger (4.1%). Thus, further evaluation of specimens may be needed to
determine the performance of this assay for these populations. Finally, there was no
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second molecular testing method used for the arbitration of discrepant results between
culture and the Xpert MRSA NxG assay, and isolates were not archived for additional
analysis of false-negative molecular assay results.
In summary, the Xpert MRSA NxG assay exhibits a clinical performance that is
superior or comparable to those of other commercially available tests for the direct
detection of MRSA in nasal swabs. Advantages of this assay include its ability to detect
more SCCmec types and mecC, which could result in increased assay sensitivity. In
addition, the assay requires minimal hands-on time and is FDA cleared for both rayon
swabs and ESwab specimens. Thus, it is adaptable for use by many clinical laboratories
to provide beneﬁcial information needed for infection prevention efforts.
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